In Vivo CRO Market By Indication (Blood Cancer, Solid Tumors and Other Indications), By Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX) and Other Models), and By Region - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI482721 | Publish Date: May 2024 | No. of Pages: 180

Global In Vivo CRO Market Companies

Recent News:

In November 2023, CCR researchers announced the development of new technology that makes T cell therapies work better against solid tumors using mouse models of pediatric and adult cancers.
In November 2023, National Cancer Institute (NC) researchers designed an approach that could potentially improve the effectiveness of T cell immunotherapies, such as CAR T cell therapy, for treating solid tumors. In animal studies, enhanced T cell therapy has been effective in treating neuroblastoma and cervical cancer.
In October 2023, Coeptis Therapeutics Holdings, Inc. announced research demonstrating the potential of its SNAP-CAR T cell platform to target multiple antigens. Research involving SNAP-CAR to demonstrate the technology’s ability to target adaptive antigens in vivo and in vitro in human tumor xenograft models.
In June 2023, the U.S. government awarded $50 million to establish the Persistent Poverty Initiative to reduce the cumulative effects of persistent poverty on cancer development by strengthening research capacity, advancing cancer prevention research, and promoting community programs.